ExpertiseUpdated on 4 April 2025
Oligodendrocyte biology and remyelination platform
business developer BIOMED at Hasselt University - Biomedical Research Institute
Diepenbeek, Belgium
About
Are you developing new therapies for neurodegenerative disease that target oligodendrocyte biology or de- and remyelination?
▶ Progress your development programs faster by building on our expertise glial cell biology, neuroscience, and lipid metabolism.
▶ Our validated models are continuously exploited in proprietary research programs and service activities for the private sector.
▶ We are keen on creating collaborative and longlasting partnerships by meeting rapidly changing needs and requirements in a flexible way and delivering on our promises.
POSSIBLE APPLICATIONS
• Test the therapeutic activity of candidate therapies on oligodendrocyte biology and remyelination in vitro at three levels: differentiation and proliferation of oligodendrocyte precursor cells (OPCs), migration behaviour of OPCs and axon-wrapping potential. Multiple conditions can be tested in parallel.
• Test the effect of therapies in a more complex multicellular brain environment using ex vivo in brain slice cultures. Multiple conditions can be tested in parallel.
• Test your candidate therapies in in vivo models which includes a battery of functional, structural, and clinical outcome measures.
Attached files
Similar opportunities
- Expertise - Blood-Brain Barrier in vitro to in vivo models - An Voets - business developer BIOMED at Hasselt University - Biomedical Research Institute - Diepenbeek, Belgium 
- Investment - Pre-seed Investment for Medtech Startup - Startup
- E-Health
- Life Science
- Biotechnology
- Therapeutic Area
 - Nuno Almeida - Co-founder & COO at Braining® - Porto, Portugal 
- Job position - Data Science Trainee | AI-powered Rehabilitation - Nuno Almeida - Co-founder & COO at Braining® - Porto, Portugal